Saturday, 7 November 2026European Markets

LISGRAFICA Stock Bullish Momentum With A 33% Rise In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of LISGRAFICA (PSI: LIG.LS) jumped by a staggering 33.33% in 21 sessions from €0.01 to €0.01 at 13:26 EST on Friday, following the last session's downward trend. PSI is dropping 1.4% to €5,784.09, after three successive sessions in a row of losses.

LISGRAFICA's last close was €0.01, 29.41% below its 52-week high of €0.01.

About LISGRAFICA

Lisgráfica - Impressão e Artes Gráficas, S.A. provides printing services in Portugal. It prints magazines, newspapers, supplements, catalogs, brochures, and telephone directories. The company was incorporated in 1973 and is headquartered in Agualva-Cacém, Portugal. Lisgrafica-Impressao e Artes Graficas is a subsidiary of Rasográfica - Comércio e Serviços Gráficos, S.A.

Earnings Per Share

As for profitability, LISGRAFICA has a trailing twelve months EPS of €-0.026.

Volatility

LISGRAFICA's last week, last month's, and last quarter's current intraday variation average was a negative 33.33%, a negative 3.97%, and a positive 22.42%.

LISGRAFICA's highest amplitude of average volatility was 33.33% (last week), 17.86% (last month), and 22.42% (last quarter).

Yearly Top and Bottom Value

LISGRAFICA's stock is valued at €0.01 at 13:26 EST, way above its 52-week high of €0.01.

More news about LISGRAFICA (LIG.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com